Angiogenesis
Research Areas
Products Related to Angiogenesis(378)
- GC49686N-desmethyl Regorafenib N-oxideCAS: 835621-12-0Purity: >90.00%
An active metabolite of regorafenib
- GC49799Apatinib-d8CAS: 2468771-43-7Purity: >92.50%
An internal standard for the quantification of apatinib
- GC49882Hemokinin 1 (human) (trifluoroacetate salt)Purity: >98.00%
A peptide agonist of NK 1 receptors
- GC60077BIO5192 hydratePurity: >99.50%
BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (Kd<10 pM).
- GC60117Cyclo(-RGDfK) TFACAS: 500577-51-5Purity: >99.50%
Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface.
- GC60197Ibrutinib deacryloylpiperidineCAS: 330786-24-8Purity: >99.50%
Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM.
- GC60807ENMD-1068 hydrochlorideCAS: 789488-77-3Purity: >98.00%
Selective protease-activated receptor 2 (PAR2) anatagonist
- GC61109NatalizumabCAS: 189261-10-7Purity: >99.00%
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1).
- GC61316tcY-NH2 TFACAS: 1262750-73-1Purity: >99.50%
tcY-NH2 ((trans-Cinnamoyl)-YPGKF-NH2) TFA is a potent selective PAR4 antagonist peptide.
- GC61323TetracCAS: 67-30-1Purity: >98.00%
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities.
- GC61456Protease-Activated Receptor-3 (PAR-3) (1-6), human TFACAS: 1872435-09-0Purity: >99.50%
Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA is a proteinase-activated receptor (PAR-3) agonist peptide.
- GC61501FSLLRY-NH2 TFAPurity: >98.00%
FSLLRY-NH2 TFA is a protease-activated receptor 2 (PAR2) inhibitor.
- GC61520Cilengitide TFACAS: 199807-35-7Purity: >99.50%
Cilengitide is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50 values of 4 nM and 79 nM, respectively.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC49562 | 4-methoxy Estrone | 58562-33-7 | >95.00% | |
An active metabolite of estrone | ||||
| GC49686 | N-desmethyl Regorafenib N-oxide | 835621-12-0 | >90.00% | |
An active metabolite of regorafenib | ||||
| GC49713 | SIKVAV (acetate) | - | >98.00% | |
A laminin α1-derived peptide | ||||
| GC49799 | Apatinib-d8 | 2468771-43-7 | >92.50% | |
An internal standard for the quantification of apatinib | ||||
| GC49808 | 12-methyl Tridecanoic Acid | 2724-57-4 | >98.00% | |
A methylated fatty acid | ||||
| GC49873 | Protectin D1 methyl ester | 934005-36-4 | >95.00% | |
An esterified form of protectin D1 | ||||
| GC49882 | Hemokinin 1 (human) (trifluoroacetate salt) | - | >98.00% | |
A peptide agonist of NK 1 receptors | ||||
| GC50075 | BTT 3033 | 1259028-99-3 | >98% | |
Selective inhibitor of integrin α2β1 | ||||
| GC50078 | BIRT 377 | 213211-10-0 | >99.50% | |
Potent negative allosteric modulator of LFA-1 | ||||
| GC50325 | BOP | 1947348-42-6 | >98% | |
BOP is a potent and selective dual α9β1/α4β1 integrin inhibitor with Kd values in the picomolar range. | ||||
| GC50642 | LDV | 1155866-55-9 | >98% | |
α4β1 (VLA-4) ligand | ||||
| GC60077 | BIO5192 hydrate | - | >99.50% | |
BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (Kd<10 pM). | ||||
| GC60117 | Cyclo(-RGDfK) TFA | 500577-51-5 | >99.50% | |
Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface. | ||||
| GC60197 | Ibrutinib deacryloylpiperidine | 330786-24-8 | >99.50% | |
Ibrutinib deacryloylpiperidine (IBT4A) is an impurity of Ibrutinib. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM. | ||||
| GC60200 | ILK-IN-3 | 6975-75-3 | >99.50% | |
ILK-IN-3 is an integrin linked kinase inhibitor with antitumor activity. | ||||
| GC60311 | PTUPB | 1287761-01-6 | >98.00% | |
PTUPB is a novel dual COX-2 and sEH inhibitor with IC 50 values of 1.26 nM and 0.9 μM, respectively. | ||||
| GC60551 | Acalabrutinib D4 | - | >98% | |
| GC60807 | ENMD-1068 hydrochloride | 789488-77-3 | >98.00% | |
Selective protease-activated receptor 2 (PAR2) anatagonist | ||||
| GC61109 | Natalizumab | 189261-10-7 | >99.00% | |
Natalizumab is a recombinant, humanized IgG4 monoclonal antibody, binds to α4β1-integrin and blocks its interaction with vascular cell adhesion molecule-1 (VCAM-1). | ||||
| GC61316 | tcY-NH2 TFA | 1262750-73-1 | >99.50% | |
tcY-NH2 ((trans-Cinnamoyl)-YPGKF-NH2) TFA is a potent selective PAR4 antagonist peptide. | ||||
| GC61323 | Tetrac | 67-30-1 | >98.00% | |
Tetrac (Tetraiodothyroacetic acid), a derivative of L-thyroxine (T4), is a thyrointegrin receptor antagonist. Tetrac blocks the actions of T4 and 3,5,3'-triiodo-L-thyronine (T3) at the cell surface receptor for thyroid hormone on integrin αvβ3. Tetra has anti-angiogenic and anti-tumor activities. | ||||
| GC61456 | Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA | 1872435-09-0 | >99.50% | |
Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA is a proteinase-activated receptor (PAR-3) agonist peptide. | ||||
| GC61501 | FSLLRY-NH2 TFA | - | >98.00% | |
FSLLRY-NH2 TFA is a protease-activated receptor 2 (PAR2) inhibitor. | ||||
| GC61520 | Cilengitide TFA | 199807-35-7 | >99.50% | |
Cilengitide is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50 values of 4 nM and 79 nM, respectively. | ||||